GSA Capital Partners LLP Makes New Investment in Kymera Therapeutics, Inc. $KYMR

GSA Capital Partners LLP acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,343 shares of the company’s stock, valued at approximately $842,000.

Several other large investors have also made changes to their positions in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kymera Therapeutics by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the last quarter. Millennium Management LLC boosted its holdings in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after purchasing an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares during the last quarter. Invesco Ltd. grew its position in Kymera Therapeutics by 13.8% during the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after purchasing an additional 5,809 shares during the period. Finally, Sei Investments Co. acquired a new stake in Kymera Therapeutics during the 2nd quarter worth about $265,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on KYMR shares. Truist Financial lifted their price objective on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Citigroup restated a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Guggenheim lifted their price target on Kymera Therapeutics from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Twenty research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $125.65.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of Kymera Therapeutics stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director directly owned 240,123 shares in the company, valued at approximately $25,573,099.50. This trade represents a 86.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,604,813 shares of company stock valued at $387,557,004 in the last 90 days. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Trading Down 0.0%

NASDAQ:KYMR opened at $121.38 on Wednesday. The stock has a 50 day moving average of $107.00 and a two-hundred day moving average of $91.12. Kymera Therapeutics, Inc. has a 12 month low of $39.84 and a 12 month high of $130.05. The firm has a market cap of $10.09 billion, a P/E ratio of -37.46 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.95) earnings per share. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.